Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
72°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Virios Therapeutics, Inc.
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics, Inc. Announces Closing of Public Offering
September 22, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics, Inc. Announces Pricing of Public Offering
September 19, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics, Inc. Announces Proposed Public Offering
September 19, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
August 10, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
August 04, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
June 01, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 05, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 17, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
September 08, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces New Social Media Profiles
August 19, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview
August 16, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
June 09, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
May 24, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics to Present at the Benzinga Global Small Cap Conference
May 07, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
April 07, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Tickers
VIRI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.